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The duodenal mucosa in patients with renal failure: Response to
1,25(OH)2D3. The structure of the duodenal mucosa was eva!-
uated in duodenal biopsy samples obtained from patients with
moderate renal failure (MRF) and in dialysis patients (HD) in an
effort to examine the possibility that changes in duodenal mucosa
may contribute to the impaired calcium absorption in renal fail-
ure (RF). The effect of therapy with 1 ,25(OH)2D, on the duode-
nal mucosa in the HD patients was also studied. The results
show that both MRF and HD patients have reduction in calcium
reabsorption and in the length of their intestinal villi and crypts
of Lieberkuhn. In the HD patients, these structural changes were
more severe. Treatment with 1 ,25(OH)2D3 produced significant
improvement in calcium reabsorption (P < 0.01) as well as in
length of villus and crypt (P < 0.02) and increased mitotic activi-
ty in the crypts (P < 0.02). Electron microscopy revealed the
microvilli to be shorter, irregularly distributed, moth-eaten, and
grainy, with these abnormalities disappearing after treatment.
The data show that duodenal mucosa in RF exhibits structural
abnormalities, which were normalized after 1 ,25(OH)2D3 thera-
py, and suggest that these derangements may play a role in the
defective calcium reabsorption in RF.
La muqueuse duodénale chez les malades en insuffisance rénale:
Réponse au 1,25(OH)2D. La structure de la muqueuse duodé-
nale a été évaluée sur des biopsies duodénales de malades at-
teints d'insuffisance rénale modérée (MFR) et de malades en
hemodialyse (HD) afin d'étudier l'hypothèse selon laquelle des
modifications de Ia muqueuse duodénale pourraient contribuer a
l'altération de l'absorption du calcium au cours de l'insuffisance
rénale. L'effet du traitement par 1 ,25(OH)2D3 sur Ia muqueuse
duodénale a été étudié chez les malades HD. Les résultats mon-
trent que les malades MRF et HD ont une diminution de
l'absorption du calcium et de Ia longueur de leurs villosités in-
testinales et de leurs cryptes de Lieberkuhn. Chez les malades
HD ces modifications de structure sont encore plus sévéres. Le
traitement par 1 ,25(OH)2D3 determine une amelioration signifi-
cative de l'absorption du calcium (P < 0,01) de méme qu'une
augmentation de Ia longueur des villosités et des cryptes (P <
0,02) et une augmentation de l'activité mitotique dans les cryptes(P < 0,02). La microscopie électronique rnontre que les micro-
villosités sont raccourcies, irrégulièrement distribuées et
d'aspect mite et granuleux, anomalies qui disparaissent après Ic
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traitement. Les résultats montrent que la muqueuse duodénale
des malades RF a des anomalies de structure qui sont normal-
isées au cours du traitement par 1 ,25(OH)2D3 et suggérent que
ces modifications peuvent jouer un role dans le deficit de au
cours de RF.
It is common to find impaired intestinal absorp-
tion of calcium in patients with chronic renal failure
[1, 2]. This abnormality has been shown to improve
after therapy with 1 ,25-dihydroxycholecalciferol
(l,25[OH]2D3) [3]. Results of in vitro studies have
attributed the improvement of the intestinal absorp-
tion of calcium with 1 ,25(OH)2D3 to enhanced pro-.
duction of an intestinal calcium binding protein [4-
10].
It is also possible that either uremia itself or the
deficiency of 1,25(OH)2D3 in uremia [11, 12] may
alter the structure of the intestinal mucosa and, as
such, may affect intestinal absorption of calcium.
Indeed, animal studies demonstrated that vitamin D
[13, 14] does affect the structure of the intestinal
mucosa. Data on the effect of uremia or vitamin D
status on the structure of the mucosa of the human
intestine are lacking.
The present study was undertaken to examine the
structure of the duodenal mucosa in patients with
renal failure and to evaluate the effect of
I ,25(OH)2D3.
Methods
Studies were carried out on eight patients. Three
of them had moderate renal insufficiency, and five
patients were treated with chronic hemodialysis
from 12 to 78 months (mean, 49 11 months).
Those patients with moderate renal failure were not
receiving any medication, and their dietary intake
of calcium was 300, 457, and 700 mg/day. The pa-
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tients on dialysis treatment were receiving folic acid
(1 mg/day) and ferrous sulfate (900 mg/day), and
their dietary intake of calcium ranged between 460
and 600 (544 25) mg/day. The clinical data de-
scribing our patients are shown in Table 1. Patients
with moderate renal failure had only baseline evalu-
ation, which included blood chemistry, intestinal
calcium absorption, and duodenal biopsy. The pa-
tients on dialysis underwent similar evaluation both
before and after 6 months of treatment with
l,25(OH)2D3. Prior to the initiation of therapy,
blood samples were obtained on three different oc-
casions over a 2-week period and served as the
baseline values for total and ionized calcium, phos-
phorus, parathyroid hormone, alkaline phospha-
tase, and creatinine. Three 24-hour urine collec-
tions were obtained in the three patients who were
not treated with hemodialysis in order to measure
endogenous creatinine clearance. During therapy
with l,25(OH)2D3, all of these parameters were
measured weekly except for alkaline phosphatase,
which was measured monthly. The concentrations
of alkaline phosphatase, phosphorus, and creatinine
were determined by standard laboratory tech-
niques, and those of calcium and magnesium by a
atomic absorption spectrophotometer (Perkin-El-
mer, model 503). Ionized calcium was measured
with an Orion electrode (SS-20, Orion Biomedical,
Cambridge, Massachusetts). The levels of PTH in
serum were determined by radioimmurioassay with
sheep antisera 478 (supplied by Dr. C. Arnaud), bo-
vine PTH labeled with iodine 125, and pooled sera
from patients with renal failure as a standard. This
assay recognizes predominantly carboxy terminal
fragments of PTH. The normal values for this assay
in our laboratory are up to 15 tlEq/ml. The in-
testinal absorption of calcium was determined by
the method of Curtis, Fellows, and Rich [15] modi-
fled in our laboratory [16]. We used oral and i.v.
administration of calcium 47. The oral isotope was
delivered with 250 mg of calcium gluconate as a car-
rier. Forearm radioactivity was measured by a
large-volume scintillation counter (Armac, Packard
Instrument Co.) 23 to 25 hours after both the oral
and i.v. doses of calcium 47 were administered, and
the fractional intestinal absorption of the ingested cal-
cium 47 was calculated in a manner previously de-
scribed [16]. The validity of this arm-counting meth-
od for calcium absorption was previously ascer-
tained in our laboratory in 10 subjects by the
simultaneous determination of fecal recovery of cal-
cium 47. The results showed that the values for cal-
cium measured by arm counting and fecal recovery
of calcium 47 fell near the line of identify [16]. Fur-
thermore, measurement of calcium 47 absorption in
the same subjects on two occasions separated by 1 to
25 months demonstrated good reproducibility [16].
Duodenal biopsies were performed with a flexible
endoscopy during the baseline period of all patients
and after 6 months of therapy in the patients under-
going long-term dialysis. Each biopsy sample was
taken on the medial wall in the second portion of the
duodenum between the valvulae conniventes. We
chose this site because the effect of vitamin D on
calcium transport is most pronounced in the proxi-
mal duodenum [17]. All studies were performed af-
ter their nature and risks were explained to the pa-
tients and informed consent was obtained.
Often, a suction instrument is considered a more
suitable technique for obtaining a small-bowel
biopsy sample because this method allows for prop-
er orientation under a dissection microscope for his-
tologic evaluation. But, the punch biopsy method
that we used, although somewhat more difficult to
orient microscopically, was proven to provide ade-
quate orientation when the slides were examined.
Table 1. Baseline clinical data on patients
Patient status Age
and no. yr Sex
Creatinine
clearance
mI/mm
Duration of renal disease
or dialysis therapy
yr Diagnosis of renal disease
With moderate renal failure
42 F 51 3 Polycystic kidneys
2 63 F 49 7 Nephrosclerosis
3 31 F 32 6 Proliferative glomerulonephritis
On long-term hemodialysis
27 M 3.5 Chronic glomerulonephritis
2 53 M 5 Nephrosclerosis
3 27 F 4.3 Chronic interstitial nephritis
4 36 M 6.5 Acute poststreptococcal
glomerulonephritis
5 26 M 1 Focal sclerosis
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The biopsy specimen was fixed in formaldehyde,
processed through paraffin, cut at 6 p, and stained
with hematoxylin-eosin and by the periodic-acid
Schiff and Schmorl techniques. All available materi-
al was embedded and examined. The entire speci-
men was cut. Depending on its size, it provided 6 to
18 sections. Examination of the histologic prepara-
tion in the permanent slide indicated adequate ori-
entation. All sections were examined, and the fol-
lowing parameters were evaluated: (1) the length of
villi and crypts (only the longest, complete, right-
angle oriented, nontangential structures were mea-
sured in each section), using a micrometer (2) the
number of columnar, goblet, Paneth, and argentaf-
fin cells (expressed as percent of total mucosal cells
in the measured villi and crypts), (3) and the num-
bers and types of cells in the lamina propria. Tissue
for electron microscopy was fixed in glutaralde-
hyde, processed through epon, cut at 600 to 700 A
and examined on an electron microscope (Hitachi
HV-11B). The entire specimen was examined in
each case, and the following parameters were eval-
uated: (I) length, shape, and uniformity of micro-
villi, (2) nature of the glycocalyx, and (3) number
and condition of mitochondria, lysosomes, endo-
plasmic reticulum, Golgi apparatus, and other or-
ganelles. Representative photographs were taken
from the tip and middle of a villus from a crypt in
each case. The light and electron microscope evalu-
ations were performed by the same pathologist. Dr.
Horowitz (Director of Pathology at St. Joseph Med-
ical Center) examined all sections twice, with a 6-
week interval between the two readings. Dr. Horo-
witz, as evaluator, was not aware of the name, diag-
nosis, or treatment status of the patients from
whom the biopsy samples were obtained. The mea-
surements were made of those villi and crypts that
were longest and showed no effect of tangential cut,
and the mitotic counts were made on the best (the
most complete or least tangential) crypts in the
specimen.
Therapy with I ,25(OH)2D3 was begun at a dose of
0.5 gIday. The dose was increased by 0.5 zg/day at
2-month intervals only if the serum calcium concen-
tration did not increase by 1.00 mg/dl. After 6
months of therapy, four of the five dialysis patients
were taking 1.5 .tg of 1,25(OH)2D3 per day. Statisti-
cal analyses were made by the Student's paired t
test.
Results
The results of the biochemical parameters, in-
testinal absorption of calcium, and light and elec-
tron microscopy of the duodenal mucosa are shown
in Tables 2 and 3 and Figs. 1 through 3. Treatment
of the five patients undergoing dialysis was associ-
ated with a rise in the serum concentrations of total
and ionized calcium, a fall in serum alkaline phos-
phatase, and a decrease in blood levels of PTH. We
emphasize, however, that the serum PTH levels
after therapy were still markedly elevated. The con-
centration of serum phosphorus showed no consis-
tent trend.
Table 2. Biochemical data on patients with moderate renal failure and patients on dialysis before and after 6 months of treatment with
1 ,25(OH)2D3'
Alkaline Parathyroid
Total calcium
,rigldl
Patient status
Ionized calcium
mg/dl
Phosphorus
rng/dl
phosphatase
BLB unitsidi
hormone
mlEq/n1 Dose of
1 ,25(OH)2D3
andno. Base AfterD3 Base AfterD3 Base AfterD3 Base AfterD3 Base AfterD3 pg/day
With moderate renal failure
1 9.50 3.90 3.3 1.1 7
2 9.25 3.84 3.1 2.3 22
3 9.80 4.04 3.4 4.0 31
Mean 9.52 3.93 3.3 2.5 20
On long-term chronic dialysis
1 9.63 10.24 3.90 4.09 3.2 2.4 4.0 3.2 260 120 0.5
2 9.10 9.80 4.20 4.07 4.1 2,8 14.7 10.5 800 485 1.5
3 8.24 9.16 3.74 3.77 3.9 4.4 77.6 52.0 310 215 1.5
4 8.45 9.31 3.54 4.02 4.3 5.0 33.2 14.4 800 498 1.5
5 6.90 9.79 2.98 4.22 5.4 5.2 4.8 3.2 540 147 1.5
Mean 8.46 9.66 3.67 4.03 4.2 4.0 26.9 16.7 542 293
SEM ±0.46 ±0.19 ±0.20 ±0.07 ±0.3 ±0.6 ±13.7 ±9.1 ±115 ±83
'Base" refers to baseline value, and "After D3" refers to after 6 months' treatment with 1 .25(OH)2D3. Normal values in our laborato-
ry are: total calcium, 9.010 10.5 mgldl; ionized calcium, 3.90 to 4.50 mgldl; inorganic phosphorus, 3.0 to 4.5 mgldl; alkaline phosphatase,
1 to 3 Bessey-Lowry-Brock units/dl; PTH, <15 zlEqIml.
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Table 3. Effect of moderate renal insufficiency and end-stage renal disease on the fractional intestinal absorption of calcium and the
morphology of the duodenal mucosa and the response to treatment with 1 ,25(OH)2D3 in end-stage renal diseases
mtestinal calcium Length of villus Length ofcrypt Mitotic activity
Patient status
and no. Base
absorption
After D3
mm mm no. mitoses/crypt
Base After D3 Base After D3 Base After D3
With moderate renal failure
1 0.19 0.50 0.20 0.60
2 0.20 0.65 0.30 0.40
3 0.17 0.55 0.22 0.10
On long-term hemodialysis
0.18 0.28 0.63 0.75 0.28 0.27 0.15 0.75
2 0.13 0.57 0.43 0.65 0.17 0.30 0.55 2.00
3 0.17 0.75 0.37 0.55 0.15 0.25 0.20 1.50
4 0.12 0.64 0.47 0.62 0.22 0.30 0.10 1.30
5 0.28 0.63 0.40 0.85 0.30 0.35 0.60 0.70
'Base" refers to baseline value, and "After D3" refers to after 6 months' treatment with 1 ,25(OH)2D3. Normal values for fraction of
ingested calcium absorbed are 0.17 to 0.37 (0.27 0.03). Normal values for length of villus are 0.5 to 1.5 mm, and for length of crypt are
0.3 to 0.5 mm [38].
The baseline determination of the fractional ab- marked increases in the fraction of intestinal cal-
sorption of calcium was below normal or at the cium absorption (from 0.18 0.03 to 0.57 0.08, P
lower range of normal values in all patients with < 0.01).
moderate renal failure and in four of the five pa- In the three patients with moderate renal failure,
tients on dialysis. All patients on dialysis showed the length of intestinal villi was in the lower range of
Fig. 1. Duodenal villi of dialysis patient no. 3 (Table 1) before (left) and after (right) 6 months l,25(OH)2D3 treatment. (Hematoxylin-
eosin stain; magnification x450)
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Fig. 2. Electron photomicrographs of the surface of mucosal cells of duodenal villi of dialysis patient no. 3 before (left) and after (right) 6
months of 1,25(OH)5D3 treatment. The microvilli before treatment are relatively short and irregular and have a granular glycocalyx
compared with microvilli after treatment. (x6000)
normal, the length of the crypts of Lieberkuhn was
abnormally low in two of these patients, and the mi-
totic activity in the crypts was comparable with that
observed in patients on dialysis prior to their treat-
ment with 1 ,25(OH)2D3. In the patients on dialysis,
the length of the crypts and villi were less than nor-
mal in four of five patients (Table 3, Fig. 1). Elec-
tron microscopy of the villi of these patients re-
vealed the microvilli, both at the tip and in the mid
zone of the villus, to be short and irregular in shape
and spacing, with a "moth eaten" appearance and
an irregular granularity of the glycocalyx (Fig. 2).
After 6 months of therapy with 1,25(OH)2D3,
there was a notable increase in the mitotic activity
in the crypts (+0.93 0.25 mitoses/crypt,P <0.02;
Fig. 3) accompanied by a distinct and significant
lengthening of the crypts (+0.07 0.02 mm, P <
0.02; Fig. 1) and of the intestinal villi (+0.22 0.06
mm, P < 0.02; Fig. 1). In addition, there was a
marked improvement in the electron microscope
appearance of the intestinal mucosa (Fig. 2)—after
treatment, the microvilli were taller, more uniform
and with a more homogeneous glycocalyx.
There were no differences among all the patients
in the numbers and types of cells of the villus sur-
face, in the numbers and types of cells of the lamina
propria, or in the numbers and condition of the vari-
ous cell organelles as examined by electron micros-
copy. Treatment with I ,25(OH)2D3 did not have an
effect on these parameters.
Discussion
The intestine and those components vital to its
absorptive abilities are major factors maintaining
the homeostasis of many ions. Limited investiga-
tions have been reported that suggest that the in-
testinal absorption of phosphate [18, 19], iron [20,
21] and zinc [22] is impaired in uremia, but consid-
erable data have accumulated to indicate that the
intestinal absorption of calcium is clearly defective
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Fig. 3. Duodenal crypts of dialysis patient no. 3 before (left) and after (right) 6 months of 1,25(OH)2D3 treatment. Note the increased
mitotic activity (—*) in the posttreatment specimen. (Hematoxylin-eosin stain; magnification x450)
in chronic renal failure [1-3], most probably due to
deficiency of l,25(OH)2D3 [11, 12]. Several authors
[3, 23, 24] have demonstrated that various vitamin
D metabolites enhance the intestinal absorption of
calcium in uremia, but the mechanisms of both the
impairment and the improvement of calcium ab-
sorption following vitamin D administration are
complex and not yet clearly understood. Wasser-
man et al [25-27] have identified an intestinal cal-
cium-binding protein (CaBP), which exists in the
glycocalyx of the microvilli, whose secretion is
stimulated by vitamin D. The role of CaBP in aug-
menting calcium entry into the cell remains, how-
ever, unclear. The improvement in calcium absorp-
tion in response to vitamin D therapy is accom-
panied also by an increase in the activity of
brushborder alkaline phosphatase and a calcium-de-
pendent ATPase [28, 29]. Recent reports [30—32]
have shown that l,25(OH)2D3 enters mucosal cells,
binds to a protein receptor, and perhaps stimulates
messenger RNA activity. Birge and Alpers [13] and
Spielvogel, Farley, and Norman [14] have also
shown in rachitic rats and chicks that vitamin D ad-
ministration stimulates mucosal cell proliferation
and an increase in villus length.
These data provide strong evidence that the ac-
tion of vitamin D appears to involve protein syn-
thesis by, and cellular proliferation of, the intestinal
mucosa. Because the bulk absorption of substances
across membranes is partially dependent on surface
area, it is indeed possible that reduction in number
or length of intestinal villi in the uremic, and hence,
vitamin-D-deficient patient, may contribute to the
impaired intestinal calcium absorption observed in
end-stage renal disease.
The results of our study demonstrate that struc-
tural abnormalities in intestinal mucosa manifested
by reduction in the lengths of intestinal villi and
crypts of Lieberkuhn may be apparent in patients
with moderate renal failure and become more
marked in patients with chronic uremia. In addition,
the latter group of patients displayed disruption of
the normal structure of the microvilli. These abnor-
malities may be due to deficiency of 1,25(OH)2D3,
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because therapy with this metabolite restored these
abnormalities to normal. It was also associated with
a significant increment in the mitotic activity of the
crypt of Lieberkuhn, suggesting an effect of
1,25(OH)2D3 on the proliferating mucosal cells in
the crypts of Lieberkuhn before the cells migrate up
the villus. It is theoretically possible that other fac-
tors such as hyperacidity in uremia could contribute
to the abnormalities in intestinal mucosa seen in our
patients. We do not have data on gastric acid secre-
tion. If the latter is important, however, in the
pathogensis of the structural changes in intestinal
mucosa, one may speculate that the improvement
noted with 1,25(OH)2D3 is partially mediated
through the effect of the sterol and gastric acid se-
cretion.
The observation that 1 ,25(OH)2D3 therapy was
associated with reversal of the abnormalities in in-
testinal mucosa and with an increase in intestinal
calcium absorption suggests that a reduction in the
absorptive surface area and the structural dis-
ruption of the microvilli contribute to the impair-
ment in intestinal absorption of calcium. Thus, it
appears that 1 ,25(OH)2D3 stimulation of intestinal
calcium absorption is the consequence of not only
its action on the calcium transport mechanism but
also of its effect on the rate of mucosal proliferation
and an increase in the effective absorptive area. The
augmentation of intestinal absorption of other sub-
stances such as phosphorus [18, 19] and zinc [23]
during therapy with 1 ,25(OH)2D3 or vitamin D for
patients with uremia provide further support for the
role of the structural derangement of the intestinal
mucosa on the overall absorptive function. Finally,
abnormalities in intestinal absorption occur in other
diseases in which the length of the villus is marked-
ly reduced. For example, Madangopolan, Shiner,
and Rowe [33] found that the average length of the
intestinal villi in patients with celiac disease is 0.13
mm and in those with untreated idiopathic stea-
torrhea is 0.18 mm. Following therapy, the length of
the villi increased.
The finding that patients with moderate renal fail-
ure did display mild abnormalities in their intestinal
mucosa suggests that they may also have a defi-
ciency of 1,25(OH)2D3. Although we did not have
measurements of blood levels of 1 ,25(OH)2D3 in the
three patients with moderate renal failure, Slato-
pol sky et al [34] have reported that the blood levels
of 1 ,25(OH)2D3 are usually normal in patients with
renal failure who have GFR's greater than 30 ml!
mm. It is, therefore, reasonable to assume that our
patients with creatinine clearances of 32 to 51 ml!
mm did not have low blood levels of 1,25(OH)2D3.
Available data indicate, however, that such patients
have evidence of target organ disease secondary to
vitamin D deficiency, including impaired intestinal
absorption [35], defective mineralization of osteoid
[36], and impaired calcemic response to PTH [37].
To reconcile such evidence of a vitamin-D-deficient
state and normal blood levels of 1 ,25(OH)2D3, one
must consider the possibilities that either the re-
quirements of the target organs for 1 ,25(OH)2D3 are
increased or that there may be a state of vitamin D
resistance in patients with moderate renal failure.
Indeed, recent studies from our laboratory are con-
sistent with these notions. Under such circum-
stances, a state of relative vitamin D deficiency
could exist despite normal blood levels of
1,25(OH)2D3. Thus, it appears that 1,25(OH)2D3
stimulation of intestinal calcium absorption is the
consequence of not only its action on the calcium
transport mechanism but also of its effect on the
rate of mucosal proliferation and an increase in the
effective absorptive area.
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